Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014

San Antonio, TX (PRWEB) September 11, 2014

The Stem Cell Institute, located in Panama City, Panama, will present an informational seminar about umbilical cord stem cell therapy on Saturday, September 20, 2014 in San Antonio, Texas at the La Cantera Hill Country Resort from 1:00 pm to 4:00 pm.

Stem Cell Institute Speakers include:

Neil Riordan PhD Umbilical Cord Stem Cell Clinical Trials for MS and Autism: Rationale and Clinical Protocols

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD Umbilical Cord Stem Cell Therapy for Arthritis, Inflammation and Sports Injuries

Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.

Special Guest Speaker:

Janet Vaughan, DDS, MS, Professional Dancer- Successful Stem Cell Therapy in Panama: A Patients Perspective

Dr. Vaughan is Board Certified in Orthodontics (Diplomate of the American Board of Orthodontics) and she is a Fellow in the International College of Dentistry.

Follow this link:
Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014

Induced Stem Cells Will Be Tested on Humans for the First Time

Back in 2006, when controversy over embryonic stem cell funding was still raging, a piece of research came along that would make the debate essentially obsolete: normal adult cells can actually be reprogrammed into stem cells. No embryos necessary. The technique went on to win its inventor the Nobel Prize. And now, after many years in the lab, a Japanese patient will the first person to receive the next-gen treatment, called induced pluripotent stem cells.

This first clinical trial for iPSCs has long been in the making. Part of its complexity is that cells are taken from each patient and then, through a series of lab procedures, transformed into stem cells. Each patient gets his or her own genetically matched iPSCs.

This individualization is a key advantage over embryonic stem cells, which have been tested in humans before. Special drugs are required to prevent patients' bodies from rejecting embryonic stem cells.

After some final safety checks and genetic tests, the first clinical trial is officially underway in Japan. Nature reports that the first patient will likely receive iPSCs within days. In total, the clinical trial has enrolled six patients, all of whom with an eye condition called macular degeneration that leads to blindness. The iPSCs will replace a deteriorated layer of cells in their retinas.

So far, the procedure has worked without serious adverse effects (usually tumors) in mice and monkeys. If it works in humans, iPSCs could be a promising new avenue for human stem cell therapy, which, if you remember, could hold the key to all sorts of incurable conditions from diabetes to Parkinson's to spinal cord injuries. This is a small first step in that direction. [Nature]

Top image: an eye with signs of macular degeneration. National Eye Institute

Read more from the original source:
Induced Stem Cells Will Be Tested on Humans for the First Time

UCSD Medical School Holding Clinical Trials For Stem Cell …

UC San Diego is initial site for first-in-human testing of implanted cell therapy.

Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc, a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes.

The trial will assess the safety and efficacy of a new investigational drug called VC-01, which was recently approved for testing by the U.S. Food and Drug Administration. The two-year trial will involve four to six testing sites, the first being at UC San Diego, and will recruit approximately 40 study participants.

The goal, first and foremost, of this unprecedented human trial is to evaluate the safety, tolerability and efficacy of various doses of VC-01 among patients with type 1 diabetes mellitus, said principal investigator Robert R. Henry, MD, professor of medicine in the Division of Endocrinology and Metabolism at UC San Diego.

He is also chief of the Section of Endocrinology, Metabolism & Diabetes at the Veterans Affairs San Diego Healthcare System.

We will be implanting specially encapsulated stem cell-derived cells under the skin of patients where its believed they will mature into pancreatic beta cells able to produce a continuous supply of needed insulin.

Previous tests in animals showed promising results. We now need to determine that this approach is safe in people.

Development and testing of VC-01 is funded, in part, by the California Institute for Regenerative Medicine, the states stem cell agency, the UC San Diego Sanford Stem Cell Clinical Center and JDRF, the leading research and advocacy organization funding type 1 diabetes research.

Type 1 diabetes mellitus is a life-threatening chronic condition in which the pancreas produces little or no insulin, a hormone needed to allow glucose to enter cells to produce energy.

It is typically diagnosed during childhood or adolescence, though it can also begin in adults. Though far less common than Type 2 diabetes, which occurs when the body becomes resistant to insulin, Type 1 may affect up to 3 million Americans, according to the JDRF.

See the article here:
UCSD Medical School Holding Clinical Trials For Stem Cell ...

Stem Cell Discovery Important for Regenerative Medicine …

A new stem cell discovery might one day lead to a more streamlined process for obtaining stem cells, which in turn could be used in the development of replacement tissue for failing body parts, according to scientists. Building on a strategy that involves reprogramming adult cells back to an embryonic state in which they again have the potential to become any type of cell, University of California/San Francisco (UCSF; California, USA), researchers have genetically removed multiple barriers to reprogramming, finding that the efficiency of generation of induced pluripotent stem (iPS) cells can be greatly increased. Reporting that: Genetic interaction studies of endocytosis or ubiquitination reveal that barrier pathways can act in linear, parallel, or feedforward loop architectures to antagonize reprogramming, the study authors submit that: These results provide a global view of barriers to human cellular reprogramming.

Qin H, Diaz A, Blouin L, Lebbink RJ, Patena W, Tanbun P, LeProust EM, McManus MT, Song JS, Ramalho-Santos M. Systematic Identification of Barriers to Human iPSC Generation. Cell. 2014 Jul 17;158(2):449-61.

Dietary supplementation of resveratrol may enhance memory performance, among older men and women.

University of California team makes discovery about how we obtain stem cells, with potential applications for creating replacement tissues and organs.

Consumed in the diet, capsaicin the active ingredient in chili peppers activates a mechanism that may reduce the risk of colorectal cancer.

Ancestral exposures to the pesticide methoxychlor may lead to adult onset kidney disease, ovarian disease and obesity in future generations.

Literacy in childhood may exert a potent influence on the risk of cognitive impairment later in life.

Type-2 diabetics who consume a diet high in salt may be at twice the risk of developing cardiovascular disease.

Eating baked or broiled fish once a week is good for the brain.

Macadamia nuts along with other tree nuts such as almonds, cashews, and pecans may confer beneficial effects for metabolic parameters of people with type-2

Read this article:
Stem Cell Discovery Important for Regenerative Medicine ...

After FDA Approval, Duchennes Muscular Dystrophy Patient Receives First Umbilical Cord Stem Cell Treatment in the …

Wichita, KS (PRWEB) September 10, 2014

Ryan Benton, a 28 year-old Duchennes muscular dystrophy patient from Wichita, Kansas, received his first umbilical cord tissue-derived mesenchymal stem cell treatment yesterday following US FDA approval of his doctors application for a single patient, investigational new drug (IND) for compassionate use.

Duchenne muscular dystrophy (DMD) is a rapidly progressive form of muscular dystrophy that occurs primarily in boys. It is caused by an alteration (mutation) in a gene, called the DMD gene, which causes the muscles to stop producing the protein dystrophin. Individuals who have DMD experience progressive loss of muscle function and weakness, which begins in the lower limbs and leads to progressively worsening disability. Death usually occurs by age 25, typically from lung disorders. There is no known cure for DMD.

This trial, officially entitled Allogeneic transplantation of human umbilical cord mesenchymal stem cells (UC-MSC) for a single male patient with Duchenne Muscular Dystrophy (DMD) marks the first time the FDA has approved an investigational allogeneic stem cell treatment for Duchennes in the United States.

Ryan received his first intramuscular stem cell injections from allergy and immunology specialist, Van Strickland, M.D at Asthma and Allergy Specialists in Wichita, Kansas. He will receive 3 more treatments this week on consecutive days. Dr. Strickland will administer similar courses to Ryan every 6 months for a total of 3 years.

This is not the first time Ryan has undergone umbilical cord mesenchymal stem cell therapy. Since 2009, Ryan has been traveling to the Stem Cell Institute in Panama for similar treatments. Encouraging results from these treatments prompted Dr. Strickland to seek out a way to treat Ryan in the United States.

The stem cell technology being utilized in this trial was developed by renowned stem cell scientist Neil H. Riordan, PhD. Dr. Riordan is the founder and president of the Stem Cell Institute in Panama City, Panama and Medistem Panama. Medistem Panama is providing cell harvesting and banking services for their US-based cGMP laboratory partner.

Funding for this trial is being provided by the Aidan Foundation, a non-profit organization founded by Dr. Riordan in 2004 to provide financial assistance for alternative therapies to people like Ryan.

About Van Strickland, MD

Dr. Strickland came to Wichita in 1979 from his fellowship at the National Jewish Hospital in Denver. Since then he has spent one year in Wyoming, one year in Dallas, Texas and one year in Lees Summit Missouri before returning to full-time practice in Wichita, Kansas.

More:
After FDA Approval, Duchennes Muscular Dystrophy Patient Receives First Umbilical Cord Stem Cell Treatment in the ...

MS stem-cell breakthrough led by Italians

'So far appears safe, without side effects'

(ANSA) - Boston, September 9 - Mesenchymal stem cell therapy to treat multiple sclerosis so far appears safe and without side effects, according to data released Tuesday and obtained through clinical trials on patients as part of the international Mesems project coordinated by University of Genoa neurologist Antonio Uccelli. The results were announced ahead of the World Congress on Treatment and Research in Multiple Sclerosis opening in Boston Wednesday through Saturday. The Mesems project involves researchers from nine countries - Italy, Spain, France, Britain, Sweden, Denmark, Switzerland, Canada and Australia. It is the first large phase II international multicentre clinical trial to determine the safety of a consensus treatment protocol established by the International Mesenchymal Stem Cells Transplantation Study Group to obtain information on its effectiveness on multiple sclerosis patients. So far, 81 patients have been involved in the project - half of the 160 needed for the whole clinical trial. About 73 - or 90% of those involved in blind testing - were given at least one injection with mesenchymal therapy or got a placebo while 51 - or 63% - were given both injections and 27 - 33% - completed the study. "The promising result is that so far none of these 27 people have suffered significant adverse events, which means that, so far, the treatment appears to be safe", said Uccelli. The neurologist warned that "caution is necessary" and that the effectiveness of the therapy can only be determined once the study is completed in 2016. Uccelli however added that preliminary studies on animals have persuaded researchers that mesenchymal stem cells "can halt inflammation on the central nervous system and probably succeed in protecting nervous tissue, even repairing it where damage is minor". Out of the 81 patients recruited so far, "28 are Italian and 10 of them have completed the study", Uccelli said, adding that all patients over the past year did relatively well except for one who was treated with placebo. The neurologist expressed the hope that "data in 2016 will give final confirmation that the therapy is effective so we can take the subsequent step with a larger phase III study aimed at demonstrating the role of stem cells as neurorepairers". Meanwhile Genoa's bioethics committee has approved a two-year extension of the project, which will be called Mesems Plus, "to verify, beyond the year of observation provided for by Mesems, the long-term safety of treatments in the study and the potential insurgence of adverse events in all those treated", said Uccelli.

Read more:
MS stem-cell breakthrough led by Italians

ViaCyte starts diabetes trial

ViaCyte is developing a drug delivery system that enables implanted pancreatic progenitor cells to survive and differentiate into functioning insulin-producing islet cells.

Correction: The number to call for more information on the diabetes clinical trial is 858-657-7039. An incorrect number was originally provided.)

ViaCyte has started a clinical trial of its diabetes treatment derived from stem cells, the first such treatment ever tested in people.

UC San Diego said Tuesday it is hosting the Phase 1 trial in partnership with San Diego-based ViaCyte. The biotech company grows islet cells from human embryonic stem cells. The cells are placed into a semi-permeable envelope and implanted into the patient. In animals, the stem cells mature into islet cells, successfully controlling blood sugar.

The treatment could provide what the company calls a virtual cure for Type 1 diabetes, which is caused by a lack of insulin-producing "islet" cells in the pancreas. About 40 people are being sought for the trial. Those interested should call Todd May at 858-657-7039.

Success would not only provide a tremendous boost for the privately held biotech company, but also California's stem cell agency, which has provided nearly $40 million in funding.

The agency, the California Institute for Regenerative Medicine, is scheduled to vote Wednesday on approving a recommended $16.6 million for ViaCyte to help with clinical trials. CIRM will eventually have to get more money as the $3 billion approved by California voters under Prop. 71 in 2004 is used up.

Paul Laikind, CEO of ViaCyte, which is making a treatment for diabetes from human embryonic stem cells.

The ViaCyte trial's goals are to assess safety and whether the cells are actually making insulin, said Paul Laikind, ViaCyte's chief executive. A longer-term goal is to determine if the cells made other hormones that regulate blood sugar levels. These are glucagon, which in contrast to insulin raises blood sugar levels, and somatostatin, which regulates both insulin and glucagon.

If the full array of hormones are produced, it's hoped that ViaCyte's product will perform like a natural pancreas, Laikind said. While the trial is starting at UCSD, Laikind said the company intends to expand it to other centers.

Original post:
ViaCyte starts diabetes trial

Combining antibodies, iron nanoparticles and magnets steers stem cells to injured organs

PUBLIC RELEASE DATE:

10-Sep-2014

Contact: Sally Stewart sally.stewart@cshs.org 310-248-6566 Cedars-Sinai Medical Center

LOS ANGELES Researchers at the Cedars-Sinai Heart Institute infused antibody-studded iron nanoparticles into the bloodstream to treat heart attack damage. The combined nanoparticle enabled precise localization of the body's own stem cells to the injured heart muscle.

The study, which focused on laboratory rats, was published today in the online peer reviewed journal Nature Communications. The study addresses a central challenge in stem cell therapeutics: how to achieve targeted interactions between stem cells and injured cells.

Although stem cells can be a potent weapon in the fight against certain diseases, simply infusing a patient with stem cells is no guarantee the stem cells will be able to travel to the injured area and work collaboratively with the cells already there.

"Infusing stem cells into arteries in order to regenerate injured heart muscle can be inefficient," said Eduardo Marbn, MD, PhD, director of the Cedars-Sinai Heart Institute, who led the research team. "Because the heart is continuously pumping, the stem cells can be pushed out of the heart chamber before they even get a chance to begin to heal the injury."

In an attempt to target healing stem cells to the site of the injury, researchers coated iron nanoparticles with two kinds of antibodies, proteins that recognize and bind specifically to stem cells and to injured cells in the body. After the nanoparticles were infused into the bloodstream, they successfully tracked to the injured area and initiated healing.

"The result is a kind of molecular matchmaking," Marbn said. "Through magnetic resonance imaging, we were able to see the iron-tagged cells traveling to the site of injury where the healing could begin. Furthermore, targeting was enhanced even further by placing a magnet above the injured heart."

The Cedars-Sinai Heart Institute has been at the forefront of developing investigational stem cell treatments for heart attack patients. In 2009, Marbn and his team completed the world's first procedure in which a patient's own heart tissue was used to grow specialized heart stem cells. The specialized cells were then injected back into the patient's heart in an effort to repair and regrow healthy muscle in a heart that had been injured by a heart attack. Results, published in The Lancet in 2012, showed that one year after receiving the stem cell treatment, heart attack patients demonstrated a significant reduction in the size of the scar left on the heart muscle.

View post:
Combining antibodies, iron nanoparticles and magnets steers stem cells to injured organs

Clinical Trial to Test Safety of Stem Cell-Derived Therapy for Type 1 Diabetes

Contact Information

Available for logged-in reporters only

Newswise Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes.

The trial will assess the safety and efficacy of a new investigational drug called VC-01, which was recently approved for testing by the U.S. Food and Drug Administration. The 2-year trial will involve four to six testing sites, the first being at UC San Diego, and will recruit approximately 40 study participants.

The goal, first and foremost, of this unprecedented human trial is to evaluate the safety, tolerability and efficacy of various doses of VC-01 among patients with type 1 diabetes mellitus, said principal investigator Robert R. Henry, MD, professor of medicine in the Division of Endocrinology and Metabolism at UC San Diego and chief of the Section of Endocrinology, Metabolism & Diabetes at the Veterans Affairs San Diego Healthcare System. We will be implanting specially encapsulated stem cell-derived cells under the skin of patients where its believed they will mature into pancreatic beta cells able to produce a continuous supply of needed insulin. Previous tests in animals showed promising results. We now need to determine that this approach is safe in people.

Development and testing of VC-01 is funded, in part, by the California Institute for Regenerative Medicine, the states stem cell agency, the UC San Diego Sanford Stem Cell Clinical Center and JDRF, the leading research and advocacy organization funding type 1 diabetes research.

Type 1 diabetes mellitus is a life-threatening chronic condition in which the pancreas produces little or no insulin, a hormone needed to allow glucose to enter cells to produce energy. It is typically diagnosed during childhood or adolescence, though it can also begin in adults. Though far less common than Type 2 diabetes, which occurs when the body becomes resistant to insulin, Type 1 may affect up to 3 million Americans, according to the JDRF. Among Americans age 20 and younger, prevalence rose 23 percent between 2000 and 2009 and continues to rise. Currently, there is no cure. Standard treatment involves daily injections of insulin and rigorous management of diet and lifestyle.

Phase I/II clinical trials are designed to assess basic safety and efficacy of therapies never before tested in humans, uncovering unforeseen risks or complications. Unpredictable outcomes are possible. Such testing is essential to ensure that the new therapy is developed responsibly with appropriate management of risks that all medical treatments may present.

This is not yet a cure for diabetes, said Henry. The hope, nonetheless, is that this approach will ultimately transform the way individuals with Type 1 diabetes manage their disease by providing an alternative source of insulin-producing cells, potentially freeing them from daily insulin injections or external pumps.

This clinical trial at UC San Diego Health System was launched and supported by the UC San Diego Sanford Stem Cell Clinical Center. The Center was recently created to advance leading-edge stem cell medicine and science, protect and counsel patients, and accelerate innovative stem cell research into patient diagnostics and therapy.

Continued here:
Clinical Trial to Test Safety of Stem Cell-Derived Therapy for Type 1 Diabetes

In directing stem cells, study shows context matters

20 hours ago by Terry Devitt When blank slate stem cells are exposed to a soft as opposed to a hard surface on which to grow, they begin to transform themselves into neurons, the large, complex cells of the central nervous system. Absent any soluble factors to direct cell differentiation, surface matters, according to new research from the lab of University of Wisconsin-Madison chemist and biochemist Laura Kiessling. Credit: Kiessling Lab/UW-Madison

Figuring out how blank slate stem cells decide which kind of cell they want to be when they grow upa muscle cell, a bone cell, a neuronhas been no small task for science.

Human pluripotent stem cells, the undifferentiated cells that have the potential to become any of the 220 types of cells in the body, are influenced in the lab dish by the cocktail of chemical factors and proteins upon which they are grown and nurtured. Depending on the combination of factors used in a culture, the cells can be coaxed to become specific types of cells.

Now, in a new study published today, Sept. 8, in the Proceedings of the National Academy of Sciences, a team of researchers from the University of Wisconsin-Madison has added a new wrinkle to the cell differentiation equation, showing that the stiffness of the surfaces on which stem cells are grown can exert a profound influence on cell fate.

"To derive lineages, people use soluble growth factors to get the cells to differentiate," explains Laura Kiessling, a UW-Madison professor of chemistry and biochemistry and stem cell expert.

Past work, she notes, hinted that the qualities of the surface on which a cell lands could exert an influence on cell fate, but the idea was never fully explored in the context of human pluripotent stem cell differentiation.

In the lab, stem cells are grown in plastic dishes coated with a gel that contains as many as 1,800 different proteins. Different factors can be introduced to obtain certain types of cells. But even in the absence of introduced chemical or protein cues, the cells are always working to differentiatebut in seemingly random, undirected ways.

The Wisconsin group, directed by Kiessling and led by chemistry graduate student Samira Musah, decided to test the idea that the hardness of a surface can make a difference. After all, in a living body, cells seek different niches with different qualities and transform themselves accordingly.

"Many cell types grow on a surface. If a cell is near bone, the environment has certain features," says Kiessling, whose groupcollaborating with UW-Madison colleagues Sean Palecek, Qiang Chang and William Murphyhas been working to produce precise, chemically defined surfaces on which to grow stem cells. "A cell will react differently if it lands near soft tissue like the brain."

To fully explore the idea that surface matters to a stem cell, Kiessling's group created gels of different hardness to mimic muscle, liver and brain tissues. The study sought to test whether the surface alone, absent any added soluble factors to influence cell fate decisions, can have an effect on differentiation.

The rest is here:
In directing stem cells, study shows context matters